Senhwa completes Phase 2 trial enrollment for COVID drug Silmitasertib

By Patrick Miller |

  • Silmitasertib is said to be safe, and can be easily administered in patients due to its oral formulation.
  • In the beginning of June 2021, Senhwa also provided Silmitasertib to Taiwan, on compassionate grounds, for patients suffering with severe COVID-19.

Drug manufacturing establishment Senhwa Biosciences, Inc. has made it to the headlines for a major announcement regarding its latest drug. The company has apparently declared that Silmitasertib, its novel oral drug, has been enrolled for its Phase 2 IIT (investigator initiated trial). For the record, this unique drug targets the protein kinase CK2 pathway and is known to possess considerable clinical potential to treat COVID-19.

As of August 4th, 2021 globally, the overall number of COVID-19 cases worldwide has crossed 200 million. As per the U.S. Centers for Disease Control and Prevention, the highly contagious Delta variant accounts for over 93 percent of the new COVID-19 cases in the United State.

Dr. John Soong, CMO (Chief Medical Officer), Senhwa Biosciences, has been quoted to state that the Delta variant or for that matter, any other variant may not impact the anti-inflammatory or anti-viral efficacy of Silmitasertib, as it targets the kinase CK2 pathway – the host protein used by the virus to replicate, and not the coronavirus proteins directly. Since the CK2 protein kinase is not known to mutate, it is an excellent target candidate for designing a potent antiviral agent, added Dr. Soong.

As per sources familiar with the knowledge of the matter, close to 20 patients afflicted with moderate COVID-19 enrolled in the study, at 2 clinical sites in the United States. The randomized, 2 arm parallel-group controlled, open-label, interventional prospective study targets to evaluate the tolerability, safety, and pharmacokinetics of 1000 mg of Silmitasertib, consumed twice daily, in patients afflicted with moderate COVID-19. This trial also aims to compare clinical benefit and time to clinical recovery across the treatment groups.

Tai-Sen Soong, CEO (Chief Executive Officer), Senhwa Biosciences, has been quoted to state that the firm is thrilled to have a fully enrolled Phase 2 IIT. Once all patients complete the study, the company is eager to commence the evaluation of the safety and efficacy of Silmitasertib, Tai-Sen Soong adds further.



Source Credits:

https://www.senhwabio.com/en/news/20210816

Comments

Post a Comment

Add your comment here

Popular posts

UK PM and Bill Gates announce new green partnership

By Hope Hill |
U.S. business magnate Bill Gates and UK Prime Minister Boris Johnson have made it to the headlines for announcing a new partnership between the government and the Breakthrough Energy Catalyst. The deal entails a substantial amount to be invested in next-gen clean energy technologies. For the unversed, Catalyst is a vital program within the Breakthrough Energy network and brings together a variety of parties – businesspersons, philanthropists, and governments, to invest in climate technologies. Catalyst focuses on four major green technology areas including long term energy storage, direct air capture, green hydrogen, and sustainable aviation fuels. As per sources, the UK government has already pledged to commit GBP 200 million to develop UK projects in these four areas as a part of the GBP 1 billion Net Zero Innovation Portfolio. Businesses that have had tie-ups with the Breakthrough Energy Catalyst will match fund GBP 200 million of that investment to help market these technologies...
Read more

Mars embarks on new initiative to reduce GHG emissions across value chain

By Patrick Miller |
Mars, Incorporated, has declared that it has a new mission in mind. The company has strengthened its commitment to accomplish a state of net zero GHG emissions spanning its overall value chain, by the year 2050. Mars’ mission aligns with the prestigious Paris Agreement, one of the most ambitious climate change action plans, that aims to limit global temperature rises up until 1.5 °C. Grant F. Reid, Chief Executive Officer, Mars, has some real-time insights into the present climate change situation. He has been quoted to state that faster initiatives must be taken at this point of time, since climate change is already well on its way to affecting people and to eliminate this threat, net zero targets must be implemented seamlessly, across whole distribution networks and the results must be depicted soon enough, instead of having to waiting for ages. Reid acknowledges the fact that a lot of loopholes exist in some net zero commitments that reduce their credibility and at large, the cli...
Read more

Munters signs turnkey project to build lithium battery laboratory

By Patrick Miller |
Energy and climate solutions leader Munters has reportedly signed a turnkey project agreement entailing the construction of a laboratory in Scandinavia. As per sources, the company plans to design and build a lithium battery laboratory in the Scandinavian region, strengthening its position as a major supplier to lithium battery producers. Munters’ step ahead may be an action initiated in favor of climate change that is increasing the demand for lithium batteries the world over. Munters’ ability to build the unit and its competence to ensure appropriate execution of the construction was a major requirement by the client. As per terms and conditions, the company will deliver the project over the forthcoming six months. The project valuation adds up to around MSEK 83.5. Klas Forsström, President and Chief Executive Officer, Munters, has been quoted to state that with increasing focus being given on minimizing carbon emissions, there’s a strong megatrend of sustainability in the market...
Read more